CCNE1 and neoplasm: Crizotinib was added to this regimen; however, he had disease progression on this chemotherapy and was referred to our service where tumor sequencing (lung metastases) revealed MET amplification, PI3KCA V344G mutation, CCNE1 amplification, and PTPRD S1845fs*2 mutation.